Summary
NPS's revenue dropped to $16.3 million in this year's first quarter from $25.2 million in the same quarter a year ago, when it had logged nonrecurring sales of inventory of a hormone injection drug to Nycomed, of France.
See the full content of this document
Extract
Nps Makes Progress On Drug Commercializations
NPS Pharmaceuticals, of Bedminster, last ...
See the full content of this document
Sponsored links
